Compare
CalciMedica, Inc. vs Chemomab Therapeutics Ltd. vs Exicure, Inc. vs NRX Pharmaceuticals, Inc.
| Latest fiscal year | CalciMedica, Inc. CALC | Chemomab Therapeutics Ltd. CMMB | Exicure, Inc. XCUR | NRX Pharmaceuticals, Inc. NRXP |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | n/a | $0 | $1.45M |
| Revenue growth (YoY) | n/a | n/a | -100.0% | n/a |
| Gross margin | n/a | n/a | n/a | 65.1% (computed) |
| Operating margin | n/a | n/a | n/a | n/m |
| Net margin | n/a | n/a | n/a | n/m |
| Net income | -$29.56M | -$8.99M | -$4.95M | -$28.62M |
| EPS (Diluted) | -$1.97 | $0.018 | -$0.79 | n/a |
| Operating cash flow | -$21.18M | -$11.13M | -$8.55M | -$14.11M |
| Free cash flow | -$21.21M | -$11.13M | -$8.56M | n/a |
| Cash & equivalents | $11.52M | $7.56M | n/a | $7.80M |
| Total assets | $13.59M | $13.81M | $14.04M | $12.96M |
| Total liabilities | $20.23M | $1.48M | $10.12M | $28.89M |
| Shareholders' equity | -$6.64M | $12.33M | $3.93M | -$15.94M |
| Return on year-end equity | n/a | -72.9% | -126.0% | n/a |
| Shares outstanding | 15.44M | n/a | 6.37M | 31.73M |
Revenue, most recent five fiscal years
| Fiscal year | CalciMedica, Inc. | Chemomab Therapeutics Ltd. | Exicure, Inc. | NRX Pharmaceuticals, Inc. |
|---|---|---|---|---|
| Latest | n/a | n/a | $0 Ended 2025-12-31 | $1.45M Ended 2025-12-31 |
| 1 year earlier | n/a | n/a | $500.0K Ended 2024-12-31 | $0 Ended 2024-12-31 |
| 2 years earlier | n/a | n/a | $0 Ended 2023-12-31 | $0 Ended 2023-12-31 |
| 3 years earlier | n/a | n/a | $28.83M Ended 2022-12-31 | n/a |
| 4 years earlier | n/a | n/a | -$483.0K Ended 2021-12-31 | n/a |